Common Questions and Answers
What will the Obagi-C Rx System do for my skin?
Prescription-strength 4% hydroquinone plus 10% L-ascorbic acid has proven aesthetic advantages:
Improves the appearance of brown spots
Accelerates skin replenishment to restore balance, radiance, and clarity to lackluster skin
Promotes skin rejuvenation from the inside out with Vitamin C, the only topical antioxidant proven to stimulate collagen synthesis
Minimizes future skin cell damage by neutralizing free radicals and protecting the skin
Maximizes antioxidant absorption due to a low pH level (low pH also means greater antioxidant stability and a longer shelf life than other leading Vitamin C products)
Why is Vitamin C important?
Vitamin C belongs to an important group of antioxidants that fight the free radicals that age your skin. Studies have shown topical Vitamin C, in the most effective form (L-ascorbic acid), can help improve sun protection, repair sun-damaged skin, reduce fine lines, stimulate collagen building, and potentially reduce discoloration of the skin.
How is the Obagi-C Rx System different from other Vitamin C products?
Many companies offer a cosmeceutical that contains Vitamin C, but it’s important for you to know that not all Vitamin C products are created equal. Clinical data show the patented Obagi-C Rx formulation delivers more L-ascorbic acid into the skin and remains in the skin longer than SkinCeuticals Phloretin CF®, another leading Vitamin C skin care product.1
Which Obagi-C Rx System is right for me?
There are 2 customized Obagi-C Rx Systems designed to treat all skin types. One system is for normal to dry skin and the other is for normal to oily skin. Ask your skin care specialist which system is right for you.
What is the difference between the 2 C-Exfoliating Day Lotions?
There are 2 C-Exfoliating Day Lotion options. One has a sunscreen with SPF 12 and the other does not have a sunscreen.
Reference: 1. Lehman PA, Investigator, Cetero Research. Evaluation of the percutaneous absorption of 14C-ascorbic acid, in vitro, using the Franz human skin finite dose model (protocol R09-0715). Data on file.